CN101142321B - 治疗眼病的方法和组合物 - Google Patents

治疗眼病的方法和组合物 Download PDF

Info

Publication number
CN101142321B
CN101142321B CN2005800467319A CN200580046731A CN101142321B CN 101142321 B CN101142321 B CN 101142321B CN 2005800467319 A CN2005800467319 A CN 2005800467319A CN 200580046731 A CN200580046731 A CN 200580046731A CN 101142321 B CN101142321 B CN 101142321B
Authority
CN
China
Prior art keywords
cfh
glu
ser
gly
pro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2005800467319A
Other languages
English (en)
Chinese (zh)
Other versions
CN101142321A (zh
Inventor
约瑟芬·赫
罗伯特·J·克莱因
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yale University
Rockefeller University
Original Assignee
Yale University
Rockefeller University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yale University, Rockefeller University filed Critical Yale University
Publication of CN101142321A publication Critical patent/CN101142321A/zh
Application granted granted Critical
Publication of CN101142321B publication Critical patent/CN101142321B/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1725—Complement proteins, e.g. anaphylatoxin, C3a or C5a
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/172—Haplotypes

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pathology (AREA)
  • Plant Pathology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
CN2005800467319A 2004-11-18 2005-11-18 治疗眼病的方法和组合物 Expired - Fee Related CN101142321B (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US62936304P 2004-11-18 2004-11-18
US60/629,363 2004-11-18
US64947905P 2005-02-02 2005-02-02
US60/649,479 2005-02-02
US67234605P 2005-04-18 2005-04-18
US60/672,346 2005-04-18
PCT/US2005/041664 WO2006062716A2 (en) 2004-11-18 2005-11-18 Methods and compositions for treating ocular disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN2012100868621A Division CN102618644A (zh) 2004-11-18 2005-11-18 治疗眼病的方法和组合物

Publications (2)

Publication Number Publication Date
CN101142321A CN101142321A (zh) 2008-03-12
CN101142321B true CN101142321B (zh) 2012-06-06

Family

ID=36578383

Family Applications (2)

Application Number Title Priority Date Filing Date
CN2005800467319A Expired - Fee Related CN101142321B (zh) 2004-11-18 2005-11-18 治疗眼病的方法和组合物
CN2012100868621A Pending CN102618644A (zh) 2004-11-18 2005-11-18 治疗眼病的方法和组合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN2012100868621A Pending CN102618644A (zh) 2004-11-18 2005-11-18 治疗眼病的方法和组合物

Country Status (14)

Country Link
US (3) US20090017029A1 (enExample)
EP (1) EP1836312B1 (enExample)
JP (2) JP2008520242A (enExample)
KR (1) KR101290621B1 (enExample)
CN (2) CN101142321B (enExample)
AT (1) ATE528410T1 (enExample)
AU (1) AU2005314461B2 (enExample)
BR (1) BRPI0518289A2 (enExample)
CA (1) CA2588270A1 (enExample)
CY (1) CY1112579T1 (enExample)
DK (1) DK1836312T3 (enExample)
ES (1) ES2375490T3 (enExample)
IL (1) IL183284A (enExample)
WO (1) WO2006062716A2 (enExample)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1565582A4 (en) 2002-11-25 2006-06-07 Sequenom Inc METHOD FOR IDENTIFYING BREAST CANCER RISK AND TREATMENTS THEREOF
US7999082B2 (en) 2004-02-10 2011-08-16 National Jewish Medical And Research Center Anti-factor B antibodies
NZ595305A (en) * 2005-02-14 2013-06-28 Univ Iowa Res Found Methods and reagents for treatment and diagnosis of age-related macular degeneration
EP1885398B1 (en) 2005-05-26 2015-07-08 The Regents of the University of Colorado, a body corporate Inhibition of the alternative complement pathway for treatment of traumatic brain injury, spinal cord injury and related conditions
US8168584B2 (en) 2005-10-08 2012-05-01 Potentia Pharmaceuticals, Inc. Methods of treating age-related macular degeneration by compstatin and analogs thereof
SI2500030T2 (sl) 2005-11-04 2018-11-30 Genentech, Inc. Uporaba inhibitorjev komplementarnih procesov za zdravljenje očesnih bolezni
US8012683B2 (en) 2006-02-13 2011-09-06 University Of Iowa Research Foundation Variants in complement regulatory genes predict age-related macular degeneration
JP5290772B2 (ja) * 2006-02-13 2013-09-18 ユニバーシティー オブ アイオワ リサーチ ファウンデーション 補体調節遺伝子における変異体が加齢性黄斑変性症を予測する
WO2007120975A2 (en) * 2006-02-13 2007-10-25 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Variants in complement regulatory genes predict age-related macular degeneration
JP5250548B2 (ja) 2006-06-21 2013-07-31 エムユーエスシー ファウンデーション フォー リサーチ ディベロップメント 疾患の治療のための補体ｈ因子の標的化
EP2046807B1 (en) * 2006-07-13 2012-03-28 University of Iowa Research Foundation Methods and reagents for treatment and diagnosis of vascular disorders and age-related macular degeneration
AU2016204271B2 (en) * 2006-07-13 2018-04-19 University Of Iowa Research Foundation Methods and reagents for the treatment and diagnosis of vascular disorders and age-related macular degeneration
ES2391788T3 (es) * 2006-07-26 2012-11-29 Yale University, Inc. Diagnóstico y tratamiento de degeneración macular relacionada con la edad
CN101173314B (zh) * 2006-10-18 2010-12-01 四川省医学科学院（四川省人民医院） 检测老年黄斑变性疾病的试剂盒
RS58233B1 (sr) 2006-11-02 2019-03-29 Genentech Inc Humanizovana anti-faktor d antitela i njihove upotrebe
GB0701213D0 (en) 2007-01-23 2007-02-28 Univ Cardiff Factor H polymorphisms in the diagnosis and therapy of inflammatory diseases such as age-related macular degeneration
US7972787B2 (en) * 2007-02-16 2011-07-05 Massachusetts Eye And Ear Infirmary Methods for detecting age-related macular degeneration
BRPI0808227A2 (pt) 2007-03-14 2014-07-08 Taligen Therapeutics Inc Anticorpo humanizado anti-fator b
JP5226256B2 (ja) * 2007-07-26 2013-07-03 ニプロ株式会社 加齢黄斑変性症の発症リスクの予測方法
CA2704447A1 (en) * 2007-11-01 2009-05-07 University Of Iowa Research Foundation Predicting amd with snps within or near c2, factor b, plekha1, htra1, prelp, or loc387715
US8114592B2 (en) 2008-03-18 2012-02-14 Cambridge Enterprise Limited Genetic markers associated with age-related macular degeneration, methods of detection and uses thereof
WO2009121065A2 (en) * 2008-03-28 2009-10-01 Apellis Ag Modulation and repletion/enhancement of the complement system for treatment of trauma
CR20170001A (es) 2008-04-28 2017-08-10 Genentech Inc Anticuerpos anti factor d humanizados
EP2540843B1 (en) * 2008-11-05 2014-07-02 Genentech, Inc. Genetic polymorphisms in age-related macular degeneration
WO2010075519A2 (en) * 2008-12-23 2010-07-01 Massachusetts Eye & Ear Infirmary Allelic variants associated with advanced age-related macular degeneration
KR100937720B1 (ko) * 2009-04-20 2010-01-20 전남대학교산학협력단 ＣＦＨ 또는 ＡｐｏＨ를 급성골수성백혈병 관해 진단용 생화학적 마커로 사용하는 방법
ME01699B (me) 2009-07-02 2014-09-20 Musc Found For Res Dev Metode za stimulaciju regeneracije jetre
MX2012005151A (es) 2009-11-05 2012-08-23 Federico Ii University Of Naples Tratamiento de hemoglobinuria nocturna paroxismica, anemias hemoliticas y estados de enfermedad que involucran hemolisis intravascular y extravascular.
EP2533797A1 (en) 2010-02-12 2012-12-19 CeMM Forschungszentrum für Molekulare Medizin GmbH Complement factor h for oxidative stress disease conditions
JP5986990B2 (ja) 2010-05-14 2016-09-06 ザ リージェンツ オブ ザ ユニヴァーシティ オブ コロラド，ア ボディ コーポレート 改善された補体レセプター２（ｃｒ２）ターゲティング基
WO2011153234A2 (en) * 2010-06-01 2011-12-08 University Of Kentucky Research Foundation Methods of inhibiting alu rna and therapeutic uses thereof
SG186397A1 (en) 2010-06-22 2013-01-30 Univ Colorado Regents Antibodies to the c3d fragment of complement component 3
WO2011163394A2 (en) 2010-06-22 2011-12-29 Apellis Pharmaceuticals, Inc. Compstatin analogs for treatment of neuropathic pain
JP2014502953A (ja) 2010-08-16 2014-02-06 ザ トラスティース オブ コロンビア ユニバーシティ イン ザ シティ オブ ニューヨーク 細胞透過性治療薬の鼻腔内送達
FR2983212A1 (fr) * 2011-11-28 2013-05-31 Lfb Biotechnologies Aptameres anti-fh, procede pour leur obtention et utilisations
FR2988298A1 (fr) * 2012-03-23 2013-09-27 Lfb Biotechnologies Facteur h pour son utilisation comme molecule antioxydante
EP2855529A4 (en) 2012-05-24 2015-12-09 Alexion Pharma Inc HUMANIZED ANTI-FACTOR B ANTIBODIES
CN102707068B (zh) * 2012-05-31 2015-03-18 北京大学 补体h因子用作甲基苯丙胺成瘾患者的基因表达产物中的应用
US10413620B2 (en) 2012-08-17 2019-09-17 The Regents Of The University Of Colorado, A Body Corporate Light-emitting versions of the monoclonal antibody to C3D (MAB 3D29) for imaging
JP2015535212A (ja) 2012-08-17 2015-12-10 ザ・リージエンツ・オブ・ザ・ユニバーシテイ・オブ・コロラド、ア・ボデイー・コーポレイト 補体活性化を検出するための組成物および方法
PL3660033T3 (pl) 2012-11-15 2021-12-06 Apellis Pharmaceuticals, Inc. Analogi kompstatyny oraz powiązane kompozycje i sposoby
JP6373963B2 (ja) 2013-03-14 2018-08-15 バクスアルタ インコーポレイテッド 移植のためのｈ因子
JP6484215B2 (ja) 2013-03-14 2019-03-13 バクスアルタ インコーポレイテッド 関節リウマチの治療のためのｈ因子
JP5721150B2 (ja) * 2013-03-14 2015-05-20 学校法人 埼玉医科大学 加齢黄斑変性症の発症リスクの予測方法
US10308687B2 (en) 2013-03-15 2019-06-04 Apellis Pharmaceuticals, Inc. Cell-penetrating compstatin analogs and uses thereof
AU2013202965B2 (en) 2013-03-15 2016-07-21 Takeda Pharmaceutical Company Limited Improved method for producing factor h from a plasma precipitation fraction
US10093978B2 (en) 2013-08-12 2018-10-09 Genentech, Inc. Compositions for detecting complement factor H (CFH) and complement factor I (CFI) polymorphisms
US20150093331A1 (en) * 2013-10-01 2015-04-02 OncoLock Co., Ltd. Biomarkers for breast cancer
KR102131973B1 (ko) * 2013-12-30 2020-07-08 주식회사 케이티 개인 건강관리 방법 및 시스템
CN107207585B (zh) * 2014-02-26 2021-12-21 阿勒根公司 补体组分c5抗体
US10155983B2 (en) 2014-03-31 2018-12-18 Machaon Diagnostics, Inc. Method of diagnosis of complement-mediated thrombotic microangiopathies
MX2016014160A (es) 2014-05-01 2017-02-16 Genentech Inc Variantes del anticuerpo anti-factor d y sus usos.
KR102314785B1 (ko) * 2015-04-21 2021-10-19 인제대학교 산학협력단 신규한 황반변성 진단용 마커 및 황반변성 진단방법
CN108431019A (zh) 2015-10-07 2018-08-21 阿佩利斯制药有限公司 给药方案
CN108472382A (zh) 2015-10-30 2018-08-31 豪夫迈·罗氏有限公司 抗-因子d抗体变体缀合物及其用途
US10407510B2 (en) 2015-10-30 2019-09-10 Genentech, Inc. Anti-factor D antibodies and conjugates
CN106018841A (zh) * 2015-11-01 2016-10-12 李倩 一种用于检测眼科疾病的试剂盒及其检测方法
PL3384049T3 (pl) * 2015-12-03 2024-01-22 Regeneron Pharmaceuticals, Inc. Sposoby powiązania wariantów genetycznych z wynikiem klinicznym u pacjentów cierpiących na zwyrodnienie plamki związane z wiekiem, leczonych anty-vegf
KR102011182B1 (ko) * 2016-10-07 2019-08-16 단국대학교 천안캠퍼스 산학협력단 익상편 과발현 유전자 및 이의 용도
CN110831544B (zh) 2017-04-07 2022-11-18 阿佩利斯制药有限公司 长效坎普他汀类似物、其组合物的给药方案及其医药用途
WO2019118938A1 (en) 2017-12-15 2019-06-20 Apellis Pharmaceuticals, Inc. Dosing regimens and related compositions and methods
US11519020B2 (en) 2018-05-25 2022-12-06 Regeneron Pharmaceuticals, Inc. Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-VEGF
CA3106838A1 (en) * 2018-07-20 2020-01-23 University Of Utah Research Foundation Gene therapy for macular degeneration
US20220146530A1 (en) * 2019-03-07 2022-05-12 Reti Mark Co., Ltd. A combination of biomarkers for diagnosing of age-related macular degeneration and use thereof
KR102333953B1 (ko) * 2020-07-10 2021-12-02 인제대학교 산학협력단 신규한 황반변성 진단용 유전자 마커
CN113293206A (zh) * 2021-07-23 2021-08-24 西安医臻生物医药科技有限公司 一种快速鉴别老年黄斑病变风险的方法及应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1311684A (zh) * 1998-07-10 2001-09-05 悉尼大学 黄斑变性中新生血管形成的预防治疗
CN1466953A (zh) * 2003-01-15 2004-01-14 哈佛东方生物医药（云南）有限公司 预防治疗老年黄斑变性的复合制剂

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1284931C (en) * 1986-03-13 1991-06-18 Henry A. Erlich Process for detecting specific nucleotide variations and genetic polymorphisms present in nucleic acids
AU2001245489A1 (en) * 2000-03-07 2001-09-17 Whitehead Institute For Biomedical Research Human single nucleotide polymorphisms
ATE412185T1 (de) * 2000-04-29 2008-11-15 Univ Iowa Res Found Diagnostika und therapeutika für makula degeneration erkrankungen
NZ595305A (en) * 2005-02-14 2013-06-28 Univ Iowa Res Found Methods and reagents for treatment and diagnosis of age-related macular degeneration

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1311684A (zh) * 1998-07-10 2001-09-05 悉尼大学 黄斑变性中新生血管形成的预防治疗
CN1466953A (zh) * 2003-01-15 2004-01-14 哈佛东方生物医药（云南）有限公司 预防治疗老年黄斑变性的复合制剂

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
Albert O. Edwards, et al..Complement Factor H Polymorphism and Age-Related Macular Degeneration.《Science》.2005,第308卷(第5720期),421-424. *
David Perez-Caballero et al.,.Clustering of Missense Mutations in the C-Terminal Region of Factor H in Atypical Hemolytic Uremic Syndrome.《Am. J. Hum. Genet.》.2001,第68卷478-484. *
Jonathan L. Haines, et al,.Complement Factor H Variant Increases the Risk of Age-Related Macular Degeneration.《Science》.2005,第308卷(第5720期),419-421. *
Pilar Sánchez-Corral et al,.Molecular basis for factor H and FHL-1 deficiency in an Italian family.《Immunogenetics》.2000,第51卷366-369. *
Robert J. Klein, et al,.Complement Factor H Polymorphism in Age-Related Macular Degeneration.《Science》.2005,第308卷(第5720期),385-389. *

Also Published As

Publication number Publication date
AU2005314461B2 (en) 2012-02-02
BRPI0518289A2 (pt) 2008-11-11
CN102618644A (zh) 2012-08-01
WO2006062716A3 (en) 2006-10-05
IL183284A0 (en) 2007-09-20
ES2375490T3 (es) 2012-03-01
ATE528410T1 (de) 2011-10-15
US20140018306A1 (en) 2014-01-16
EP1836312A2 (en) 2007-09-26
US20090017029A1 (en) 2009-01-15
US20120135000A1 (en) 2012-05-31
CN101142321A (zh) 2008-03-12
IL183284A (en) 2014-09-30
KR101290621B1 (ko) 2013-07-29
CA2588270A1 (en) 2006-06-15
KR20070105969A (ko) 2007-10-31
AU2005314461A1 (en) 2006-06-15
EP1836312B1 (en) 2011-10-12
JP2012080900A (ja) 2012-04-26
CY1112579T1 (el) 2016-02-10
DK1836312T3 (da) 2012-03-12
WO2006062716A2 (en) 2006-06-15
JP2008520242A (ja) 2008-06-19
HK1113690A1 (en) 2008-10-10

Similar Documents

Publication Publication Date Title
CN101142321B (zh) 治疗眼病的方法和组合物
AU2021261909B2 (en) Antisense oligomers for treatment of conditions and diseases
KR101778036B1 (ko) 전립선암 마커로서의 포스포디에스테라제 4ｄ7
KR102110469B1 (ko) 악성의 호르몬 민감성 전립선 암에 대한 마커로서의 포스포디에스테라제 4ｄ7
AU2016352836A1 (en) Oligonucleotides for inducing paternal UBE3A expression
KR20220012230A (ko) 스플라이싱 및 번역을 조절하기 위한 방법 및 조성물
KR20220113743A (ko) 병태 및 질환의 치료를 위한 안티센스 올리고머
AU2016325030A1 (en) Novel biomarkers and methods of treating cancer
TW202536179A (zh) 用於調節ube3a-ats之化合物及方法
WO2006022629A1 (en) Methods of identifying risk of type ii diabetes and treatments thereof
KR20090087486A (ko) 타입 ２ 당뇨병의 유전적 감수성 변이
CN101631876A (zh) 2型糖尿病的遗传易感性变体
CN101151371B (zh) 治疗中的逆转录转座子抑制
KR20230074214A (ko) 지방간 질환의 치료 방법
KR20230005933A (ko) Atxn1을 조정하는 화합물 및 방법
WO2006022636A1 (en) Methods for identifying risk of type ii diabetes and treatments thereof
CN115362255A (zh) 用无七之子2(sos2)抑制剂治疗眼科疾患
KR102642320B1 (ko) 항암제에 대한 내성 진단용 조성물
KR20170116009A (ko) 전립선암의 진단을 위한 신규한 rna-바이오마커 시그니처
KR20240006511A (ko) 포스포디에스테라제 3b (pde3b) 억제제를 이용한 간 질환 치료 방법
KR101474053B1 (ko) 골다공증 또는 골다공성 골절 발생 위험도 예측용 다형성 마커
CN112771162A (zh) 用剪接转换寡核苷酸靶向kit诱导肥大细胞凋亡
CN111556894A (zh) 用于调控gsk3b表达的寡核苷酸
EA048246B1 (ru) Способ лечения жировой болезни печени
CN114053413A (zh) 一种col4a4基因作为急性缺血性卒中治疗靶点的应用

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20120606

Termination date: 20151118

EXPY Termination of patent right or utility model